BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23330407)

  • 21. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When should cardiologists suspect Anderson-Fabry disease?
    Gambarin FI; Disabella E; Narula J; Diegoli M; Grasso M; Serio A; Favalli BM; Agozzino M; Tavazzi L; Fraser AG; Arbustini E
    Am J Cardiol; 2010 Nov; 106(10):1492-9. PubMed ID: 21059442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease].
    Kes VB; Cesarik M; Zavoreo I; Butković SS; Kes P; Bašić-Jukić N; Rački S; Jakić M; Delić-Brkljačić D; Jukić Z; Trkanjec Z; Šerić V; Solter VV; Bielen I; Bašić S; Demarin V; ; ; ;
    Acta Med Croatica; 2014 Apr; 68(2):223-32. PubMed ID: 26012164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurological manifestations in Fabry's disease.
    Møller AT; Jensen TS
    Nat Clin Pract Neurol; 2007 Feb; 3(2):95-106. PubMed ID: 17279083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease. A case report.
    Kotnik J; Kotnik F; Desnick RJ
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabry disease: a review of current management strategies.
    Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
    QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular pathology and clinical manifestations of Fabry disease].
    Rákóczi E; Görögh S; Grubits J; Erdos M; Garzuly F; Hahn K; Bencsik K; Vécsei L; Trinn C; Kristóf E; Mogyorósy G; Tóth B; Maródi L
    Orv Hetil; 2007 Jun; 148(23):1087-94. PubMed ID: 17545117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fabry's disease.
    El-Abassi R; Singhal D; England JD
    J Neurol Sci; 2014 Sep; 344(1-2):5-19. PubMed ID: 25106696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fabry disease--a provocation for pediatrics].
    Hoffmann B; Mayatepek E
    Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
    Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
    Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
    Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ocular findings in Fabry's disease].
    Kuzman T; Juri J; Mrsić M; Jeren-Strujić B; Mandić Z; Sikić J
    Acta Med Croatica; 2006; 60(2):163-6. PubMed ID: 16848212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiac involvement in Fabry's disease - typical disease course and diagnostic problems].
    Owsiak M; Kwiecień-Sobstel A; Mirek-Bryniarska E; Bryniarski L
    Kardiol Pol; 2011; 69(4):364-6. PubMed ID: 21523672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.